(Q45833631)

English

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Laurent Boccon-Gibod

5

object named as

Laurent Boccon-Gibod

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

author name string

Jan-Erik Damber

1

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

Teuvo L J Tammela

2

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

Peter Iversen

3

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

Per-Anders Abrahamsson

4

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

Tine Kold Olesen

6

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

Egbert van der Meulen

7

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

Bo-Eric Persson

8

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

language of work or name

0 references

publication date

1 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

80

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

1

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

174-180

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Management of advanced prostate cancer: can we improve on androgen deprivation therapy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Prospective study of sex hormone levels and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Hormonal predictors of prostate cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

The role of testosterone in the pathogenesis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.092

7 January 2021

Identifiers

10.1016/J.UROLOGY.2012.01.092

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22748873

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45833631&oldid=2084949614"